TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
BHVN

Biohaven Ltd.

Healthcare · Biotechnology

13.90$ +15.6% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Biohaven Ltd. (BHVN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 77.2% of the shares are freely tradable; institutional investors hold 97.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 97.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 11.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 77.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 16.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 151Mio.

Largest Shareholders

Institutions

Institutions BHVN
Name Stake (%) Shares Change (%) Date
HHG PLC 11.61 17,534,612 +1,145.9 03/31/2026
BlackRock Inc 7.43 11,222,407 +18.8 03/31/2026
Suvretta Capital Management, LLC 6.81 10,286,937 +0.0 03/31/2026
Stifel Financial Corp 6.58 9,940,885 +0.0 03/31/2026
State Street Corp 4.38 6,618,803 +15.8 03/31/2026
D. E. Shaw & Co LP 2.77 4,190,195 +47.2 06/30/2026
StemPoint Capital LP 2.11 3,188,982 +0.0 03/31/2026
Royalty Pharma Sub-Manager, LLC 1.94 2,936,507 +0.0 06/30/2026

Funds

Funds BHVN
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Biotech ETF 2.65 4,000,571 -1.1 08/31/2026
iShares Russell 2000 ETF 2.27 3,421,605 -0.6 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?